Treatment results of chronic delta hepatitis patients

Aim: Chronic delta hepatitis has been reported in 2,3-2,7% of studies in our country. Chronic delta hepatitis cases progress rapidly and show poor prognosis and the rate of developing cirrhosis are 70% in 5-10 years. The success of interferon (IFN) based treatment regimens for the treatment of delta hepatitis is about 30%. However, there is frequent relapse at the end of therapy, unless HBsAg seroconversion is developed. Material and Methods: In this study, patients with chronic Delta hepatitis were evaluated retrospectively and the patients who were treated successfully were reviewed by reviewing the literature. Anti-HDV was positive in 243 (4.44%) of 5471 HBsAg positive patients who applied between 2012-2017. Peg-IFN alpha 2a was given if dominated by HDV and Peg-IFN alpha 2a and tenofovir disoproksil were given if dominant by HBV. Results: The patients who were treated were evaluated and at the end of the treatment 10 of the patients had HBs Ag seroconversion and anti-HBs were positive. Conclusion: Effective and timely treatment of chronic hepatic hepatitis cases will prevent the complications related to liver failure and prevent death